Aprocitentan is a selective dual endothelin receptor antagonist approved by the FDA in 2024 for the treatment of hypertension, specifically in adults with resistant hypertension not adequately controlled by other antihypertensive therapies. It targets the endothelin system, a key regulator of blood pressure, by blocking endothelin type A and B receptors. This action promotes vasodilation, reduces blood pressure, and may help mitigate associated cardiovascular risks. As a pharmaceutical compound (CAS: 946150-57-8, molecular formula: C₂₈H₂₇F₃N₄O₅S), it is available as a research reagent with high purity for laboratory use.